| 11.53 -0.25 (-2.12%) | 12-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.13 | 1-year : | 18.3 |
| Resists | First : | 13.81 | Second : | 15.67 |
| Pivot price | 11.99  |
|||
| Supports | First : | 10.81 | Second : | 9 |
| MAs | MA(5) : | 11.81 |
MA(20) : | 11.89 |
| MA(100) : | 12.84 |
MA(250) : | 17.42 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 45.1 |
D(3) : | 49 |
| RSI | RSI(14): 43.1 |
|||
| 52-week | High : | 29.7 | Low : | 10.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QTRX ] has closed above bottom band by 23.7%. Bollinger Bands are 52.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.87 - 11.94 | 11.94 - 12.01 |
| Low: | 11.38 - 11.46 | 11.46 - 11.52 |
| Close: | 11.42 - 11.54 | 11.54 - 11.65 |
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
Sun, 08 Dec 2024
Quanterix Corporation Announcement: If You Have Suffered - GlobeNewswire
Sun, 08 Dec 2024
Pier Capital LLC Has $6.63 Million Holdings in Quanterix Co. (NASDAQ:QTRX) - MarketBeat
Wed, 04 Dec 2024
QUANTERIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Tue, 03 Dec 2024
Quanterix Corporation Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Fri, 22 Nov 2024
Quanterix Announces Receipt of Expected Notice from Nasdaq - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 38 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 88.6 (%) |
| Shares Short | 1,990 (K) |
| Shares Short P.Month | 2,470 (K) |
| EPS | -1.04 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.77 |
| Profit Margin | -30.8 % |
| Operating Margin | -38.2 % |
| Return on Assets (ttm) | -7.9 % |
| Return on Equity (ttm) | -11.5 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.36 |
| EBITDA (p.s.) | -1.2 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -35 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -11.09 |
| PEG Ratio | 0 |
| Price to Book value | 1.31 |
| Price to Sales | 3.42 |
| Price to Cash Flow | -12.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|